The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a MEK inhibitor, particularly trametinib, particularly for use in the treatment of a proliferative disease. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a proliferative disease； methods of treating a proliferative disease in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination； use of such combination for the treatment of proliferative disease； pharmaceutical compositions comprising such combination and commercial packages thereto.本發明係關於一種醫藥組合，其包含(a) 如本文中所定義之Raf抑制劑或其醫藥學上可接受之鹽及(b) MEK抑制劑，尤其曲美替尼，尤其用於治療增生性疾病。本發明亦關於此類組合用於製備用於治療增生性疾病之藥劑之用途；治療有需要個體之增生性疾病之方法，其包含向該個體投與聯合治療有效量之該組合；此類組合用於治療增生性疾病之用途；包含此類組合之醫藥組合物及其市售套裝。
